Avoro Capital Advisors’s Rocket Pharmaceuticals RCKT Stock Holding History

Avoro Capital Advisors’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-1,200,000	Closed	-$15.1M	–	39
2024 Q4	$15.1M	Buy	+1,200,000	New	+$18.1M	0.21%	37
2024 Q2	–	Sell	-1,260,900	Closed	-$34M	–	44
2024 Q1	$34M	Hold	1,260,900	–	–	0.4%	39
2023 Q4	$37.8M	Buy	1,260,900 +10,900	+0.9%	+$241K	0.52%	27
2023 Q3	$25.6M	Buy	+1,250,000	New	+$22.7M	0.4%	28
2019 Q4	–	Sell	-285,714	Closed	-$3.33M	–	36
2019 Q3	$3.33M	Hold	285,714	–	–	0.14%	33
2019 Q2	$4.29M	Buy	+285,714	New	+$4.99M	0.15%	32

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Avoro Capital Advisors's RCKT Position: Q1 2025 in Review

Avoro Capital Advisors sold out of Rocket Pharmaceuticals (RCKT) in Q1 2025, closing a stake of 1,200,000 shares — an estimated $15.1M sold.

Avoro Capital Advisors first reported a position in RCKT in Q2 2019 and held it in 6 quarters. The position peaked at $37.8M in Q4 2023. 236 funds tracked by Wall St. Rank hold RCKT as of Q1 2025.

Avoro Capital Advisors reported no remaining Rocket Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Avoro Capital Advisors sold 1,200,000 Rocket Pharmaceuticals shares in Q1 2025, an estimated $15.1M.
Avoro Capital Advisors first reported a position in Rocket Pharmaceuticals in Q2 2019 and held it in 6 quarters.
Avoro Capital Advisors's Rocket Pharmaceuticals position peaked at $37.8M in Q4 2023.
236 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q1 2025.

Based on Avoro Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.